Lawmakers hear experts and families as bill would require coverage for PANS/PANDAS treatments
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
House Bill 292 would require private insurers to cover evaluation and specified treatments for pediatric autoimmune neuropsychiatric disorders (PANS/PANDAS), including IVIG in qualifying cases; experts and parents described delayed denials and the clinical rationale, and the committee adopted an amendment adding Medicaid coverage.
Representative Julie Clombe introduced House Bill 292, which would require private insurers to cover evaluation and treatment for PANS and PANDAS, including antimicrobials, behavioral therapies, immunomodulatory medicines, plasma exchange and intravenous immunoglobulin (IVIG) when clinically indicated.
Dr. Angela Tang (adjunct clinical associate professor at Stanford’s immune behavioral health clinic) testified that rapid treatment can prevent long‑term disability, described clinical guidelines and small controlled trials that support IVIG in severe or refractory cases, and recounted personal experience navigating denials. Tang said delays in access correlate with worse outcomes and that states that passed coverage laws saw reductions in appeals and faster treatment access; she urged support for HB 292.
Insurance Director Heather Carpenter described existing tools — including an external independent review process and recent prior‑authorization reform (SB 133, effective Jan. 1, 2027) — that allow appeals and review for medically necessary services regulated by the division. Medicaid program manager Tricia Skitt said EPSDT and related Medicaid provisions can cover medically necessary services for beneficiaries under age 21.
Two public witnesses — Bonnie Bailey (parent and emergency medical professional) and Kristen Coletti Giesler (family nurse practitioner) — described long delays, financial burdens and clinical deterioration when needed IVIG or other immunomodulatory treatments were initially denied by insurers. Bailey said IVIG “saved her child’s brain” after months of struggle and urged prompt coverage.
The committee considered three amendments. Amendment 1 (which would include these treatments under Alaska Medicaid as well as private insurance) was adopted by the committee. Amendment 3, which would have addressed a state assumption of cost if federal rules change, was withdrawn. The committee set HB 292 aside and extended the amendment deadline; the sponsor and staff will provide follow‑up data requested by members.
Next steps: the bill will return to committee with additional clarifications requested by members about how the statute references clinical guidelines and what appeal timelines or prior‑authorization changes mean for timely access to care.